Background: Paradoxical Adverse Events (PAEs) during biological therapy are characterized by the onset of a new inflammatory disease or by the exacerbation of the preexisting condition (with a different morphology or localization) while treating the patient with a class-agent proven efficacious for both conditions. They can be divided in two subgroups: “true PAE” characterized by the previously proven efficacy of the biological agent for the PAE and “borderline PAE” defined by the development of an inflammatory condition where the biological agent has not a proven efficacy. Methods: systematic search of English databases in order to identify true and borderline-skin PAE under anti IL-17 therapy. Results: We retrieved 58 patients affected by skin-PAE during anti-IL-17 therapy, 40 cases classified as True-PAE and 18 as Borderline-PAE., with a mean age of onset of 51 years. Secukinumab was the most frequent agent associated to skin-PAE and mean onset of the skin-PAE was 18 weeks. Conclusion: True-skin-PAE occur during anti Il-17 therapy, the underlaying immunological mechanism is not yet known, but pustular variants of psoriasis seem to be more prevalent; withdrawal of the anti-IL-17 therapy has been mainly performed and other therapies such as antiIL-23 biologics seem to control both the underlying disease and the true-skin-PAE. Further studies are needed in order to better understand the immunological mechanism involved.
{"title":"Skin Related Paradoxical Adverse Events (Mainly Psoriasis) During Il-17 Blockage: A Systematic Review","authors":"Alexandra Maria Giovanna Brunasso, M. Montinari","doi":"10.46889/jdr.2023.4208","DOIUrl":"https://doi.org/10.46889/jdr.2023.4208","url":null,"abstract":"Background: Paradoxical Adverse Events (PAEs) during biological therapy are characterized by the onset of a new inflammatory disease or by the exacerbation of the preexisting condition (with a different morphology or localization) while treating the patient with a class-agent proven efficacious for both conditions. They can be divided in two subgroups: “true PAE” characterized by the previously proven efficacy of the biological agent for the PAE and “borderline PAE” defined by the development of an inflammatory condition where the biological agent has not a proven efficacy. Methods: systematic search of English databases in order to identify true and borderline-skin PAE under anti IL-17 therapy. Results: We retrieved 58 patients affected by skin-PAE during anti-IL-17 therapy, 40 cases classified as True-PAE and 18 as Borderline-PAE., with a mean age of onset of 51 years. Secukinumab was the most frequent agent associated to skin-PAE and mean onset of the skin-PAE was 18 weeks. Conclusion: True-skin-PAE occur during anti Il-17 therapy, the underlaying immunological mechanism is not yet known, but pustular variants of psoriasis seem to be more prevalent; withdrawal of the anti-IL-17 therapy has been mainly performed and other therapies such as antiIL-23 biologics seem to control both the underlying disease and the true-skin-PAE. Further studies are needed in order to better understand the immunological mechanism involved.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79352338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Couissi, H. Baybay, Sara El Loudi, Z. Douhi, Meryem Soughi, F. Zahra Mernissi
Background: Pemphigus is a rare autoimmune mucocutaneous bullous disease. It includes pemphigus vulgaris and pemphigus superficial. Rituximab is an antibody that targets CD-20 molecules on B-cells and has been approved as a first-line treatment for moderate to severe pemphigus vulgaris. The aim of our study is to evaluate the efficacy and safety of Rituximab in the treatment of pemphigus patients. Materials and methods: It is a prospective study extending over a period of 6 years from December 2016 to July 2022, including all patients with severe or treatment-resistant pemphigus who received treatment with RITUXIMAB at a dose of 375 mg/m2/week for 4 weeks (lymphoma protocol) or 2 infusions of 1 g at 15-day intervals (rheumatoid arthritis protocol (PR protocol)), combined with oral corticosteroid therapy at a dose of 0.5 to 1 mg/kg/day (depending on severity) with a 6-month taper. Maintenance treatment depends on the IFI level. In the case of high levels, an infusion of 1 g after 6 months is given and in the case of low levels, an infusion of 500 mg after 1 year is given. Consent and authorization from the local ethics committee were required. The datan were entered into an Excel program and analyzed via Epi info version 7 software. Patients receiving CNSS health insurance were excluded. Results: 63 patients with pemphigus were using Rituximab (PR protocol: 44 lymphoma protocol: 19), 3 of which are currently being followed up (< 6 months). 44 cases of pemphigus vulgaris of which 15 received the lymphoma protocol and 29 received the PR protocol, 14 cases of superficial pemphigus of which 4 cases received the lymphoma protocol, and 10 cases of PR protocol and 5 cases of vegetative pemphigus received the PR protocol.
背景:天疱疮是一种罕见的自身免疫性皮肤粘膜大疱性疾病。它包括寻常性天疱疮和浅表性天疱疮。利妥昔单抗是一种靶向b细胞CD-20分子的抗体，已被批准作为中重度天疱疮的一线治疗药物。本研究的目的是评价利妥昔单抗治疗天疱疮患者的有效性和安全性。材料与方法:这是一个前瞻性研究延长一段6年从2016年12月到2022年7月,包括所有严重或难治性天疱疮患者接受治疗的剂量与利妥昔单抗375 mg / m2 /星期4周(淋巴瘤协议)或2注入1 g每隔15天(类风湿性关节炎协议(PR协议)),结合口服皮质类固醇疗法剂量为0.5到1毫克/公斤/天(根据严重程度)和6个锥形。维持治疗取决于IFI水平。在高水平的情况下，6个月后输注1 g，在低水平的情况下，1年后输注500 mg。需要得到当地伦理委员会的同意和授权。将数据输入Excel程序，并通过Epi info version 7软件进行分析。接受CNSS健康保险的患者被排除在外。结果:63例天疱疮患者使用利妥昔单抗治疗(PR方案:44例淋巴瘤方案:19例)，其中3例目前正在随访(< 6个月)。寻常型天疱疮44例，其中淋巴瘤方案15例，PR方案29例;浅表性天疱疮14例，其中淋巴瘤方案4例;PR方案10例，植物性天疱疮5例，PR方案5例。
{"title":"Comparative Study Between Two Protocols of Rituximab in Pemphigus: About 63 Cases","authors":"I. Couissi, H. Baybay, Sara El Loudi, Z. Douhi, Meryem Soughi, F. Zahra Mernissi","doi":"10.46889/jdr.2023.42010","DOIUrl":"https://doi.org/10.46889/jdr.2023.42010","url":null,"abstract":"Background: Pemphigus is a rare autoimmune mucocutaneous bullous disease. It includes pemphigus vulgaris and pemphigus superficial. Rituximab is an antibody that targets CD-20 molecules on B-cells and has been approved as a first-line treatment for moderate to severe pemphigus vulgaris. The aim of our study is to evaluate the efficacy and safety of Rituximab in the treatment of pemphigus patients. Materials and methods: It is a prospective study extending over a period of 6 years from December 2016 to July 2022, including all patients with severe or treatment-resistant pemphigus who received treatment with RITUXIMAB at a dose of 375 mg/m2/week for 4 weeks (lymphoma protocol) or 2 infusions of 1 g at 15-day intervals (rheumatoid arthritis protocol (PR protocol)), combined with oral corticosteroid therapy at a dose of 0.5 to 1 mg/kg/day (depending on severity) with a 6-month taper. Maintenance treatment depends on the IFI level. In the case of high levels, an infusion of 1 g after 6 months is given and in the case of low levels, an infusion of 500 mg after 1 year is given. Consent and authorization from the local ethics committee were required. The datan were entered into an Excel program and analyzed via Epi info version 7 software. Patients receiving CNSS health insurance were excluded. Results: 63 patients with pemphigus were using Rituximab (PR protocol: 44 lymphoma protocol: 19), 3 of which are currently being followed up (< 6 months). 44 cases of pemphigus vulgaris of which 15 received the lymphoma protocol and 29 received the PR protocol, 14 cases of superficial pemphigus of which 4 cases received the lymphoma protocol, and 10 cases of PR protocol and 5 cases of vegetative pemphigus received the PR protocol.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86395668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Currently the FDA adopts a zero-tolerance policy toward sun exposure in order to prevent skin cancer and premature skin aging (photoaging). This is apparently based on classical concept that damage from sunlight, a carcinogen, is cumulative and un-reparable. Such concept is apparently flawed both theoretically and in reality. The nature’s design to achieve genomic stability of body health and appearance for smooth passage of generations in our normal daily lives would require virtually complete repair of damages of DNA and other tissue components from daily Exposure to Non-Burning Sunlight (ENS). In other words, ENS is generally not expected to cause skin cancer and photoaging. Such notion is evidenced by, for example, low worldwide skin-cancer incidences, severe sunburn as overwhelming skin-cancer etiology, and intrinsic aging as overwhelming skin aging. Since ENS can provide numerous health benefits, such exposure can be regarded as healthy sun exposure and used to help prevent skin cancer. Due to unintended sunburn effect, use of sunscreens for intense intermittent exposure is strongly discouraged. As photoaging and skin cancer may be closely related, some questions related to conventional theories and practices in photoaging are also raised. They include the following: Schuster’s pioneering study in 1975; invalidation of accelerated aging theory; questionable theory on etiology of wrinkles and age spots; Fisher’s studies on metalloproteinases; bolus doing vs constant-rate dosing in irradiation; moisturizers as anti-photoaging/anti-cancer agents; inclusion of blood and water in skin-aging exosome; wind effect; differences in usage pattern between countries in sunscreen evaluation; replacement of UVA in tanning beds.
{"title":"Prevention of Skin Cancer: Healthy Sun Exposure and No sunscreen for Intense Intermittent Exposure; Photoaging Theories Questioned and New Strategies","authors":"W. L. Chiou","doi":"10.46889/jdr.2022.3304","DOIUrl":"https://doi.org/10.46889/jdr.2022.3304","url":null,"abstract":"Currently the FDA adopts a zero-tolerance policy toward sun exposure in order to prevent skin cancer and premature skin aging (photoaging). This is apparently based on classical concept that damage from sunlight, a carcinogen, is cumulative and un-reparable. Such concept is apparently flawed both theoretically and in reality. The nature’s design to achieve genomic stability of body health and appearance for smooth passage of generations in our normal daily lives would require virtually complete repair of damages of DNA and other tissue components from daily Exposure to Non-Burning Sunlight (ENS). In other words, ENS is generally not expected to cause skin cancer and photoaging. Such notion is evidenced by, for example, low worldwide skin-cancer incidences, severe sunburn as overwhelming skin-cancer etiology, and intrinsic aging as overwhelming skin aging. Since ENS can provide numerous health benefits, such exposure can be regarded as healthy sun exposure and used to help prevent skin cancer. Due to unintended sunburn effect, use of sunscreens for intense intermittent exposure is strongly discouraged. As photoaging and skin cancer may be closely related, some questions related to conventional theories and practices in photoaging are also raised. They include the following: Schuster’s pioneering study in 1975; invalidation of accelerated aging theory; questionable theory on etiology of wrinkles and age spots; Fisher’s studies on metalloproteinases; bolus doing vs constant-rate dosing in irradiation; moisturizers as anti-photoaging/anti-cancer agents; inclusion of blood and water in skin-aging exosome; wind effect; differences in usage pattern between countries in sunscreen evaluation; replacement of UVA in tanning beds.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83940425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Platelet Rich Plasma (PRP) is an autologous concentration of human platelets contained in a small volume of plasma, has been proposed as a potential adjuvant therapy to Female Pattern Hair Loss (FPHL). Despite the widespread use of PRP in numerous fields of medicine, there have been few studies that investigated the clinical efficacy of PRP in FPHL. Methods: Fourteen female patients, age ranged from 20-45 years, diagnosed with female pattern hair loss were enrolled in this single-blinded randomized placebo-controlled study. Fourteen patients were divided randomly into two groups: Group 1 were injected with PRP using insulin syringe and group 2 were injected with normal saline as placebo. All patients were followed at 3 and 6 months after the last treatment sessions. Of the total subjects enrolled, on ten subjects completed the study. In total, 7 (70%) individuals received PRP and 3 (30%) received placebo. During all the treatment sessions, there were no severe adverse events reported. The study yielded investigator, subject and photographic assessments. Results: On the basis of the independent-blinded investigator assessment of change in the patient’s scalp hair growth from baseline, treatment in PRP group demonstrated as scale 1 improvement in 5 subjects (26-50%) and scale 2 improvement in 2 subjects (51-75%) at the final visit as compared to baseline (Fig. 1,2). In contrast, in the placebo group were rated as scale 0 improvement (0-25%). Conclusion: PRP injection for FPHL is a simple, cost-effective and feasible treatment option with good safety profile. However more randomized and multicentric trials with a large number of patients will be required to prove the validity of these results, to obtain these answers and to get more robust statistical results.
{"title":"Evaluation of Platelet Rich Plasma for Treatment of Female Pattern Hair Loss: A Placebo-Controlled Case Study","authors":"Ruri D. Pamela","doi":"10.46889/jdr.2022.3303","DOIUrl":"https://doi.org/10.46889/jdr.2022.3303","url":null,"abstract":"Background: Platelet Rich Plasma (PRP) is an autologous concentration of human platelets contained in a small volume of plasma, has been proposed as a potential adjuvant therapy to Female Pattern Hair Loss (FPHL). Despite the widespread use of PRP in numerous fields of medicine, there have been few studies that investigated the clinical efficacy of PRP in FPHL.\u0000\u0000Methods: Fourteen female patients, age ranged from 20-45 years, diagnosed with female pattern hair loss were enrolled in this single-blinded randomized placebo-controlled study. Fourteen patients were divided randomly into two groups: Group 1 were injected with PRP using insulin syringe and group 2 were injected with normal saline as placebo. All patients were followed at 3 and 6 months after the last treatment sessions. Of the total subjects enrolled, on ten subjects completed the study. In total, 7 (70%) individuals received PRP and 3 (30%) received placebo. During all the treatment sessions, there were no severe adverse events reported. The study yielded investigator, subject and photographic assessments.\u0000\u0000Results: On the basis of the independent-blinded investigator assessment of change in the patient’s scalp hair growth from baseline, treatment in PRP group demonstrated as scale 1 improvement in 5 subjects (26-50%) and scale 2 improvement in 2 subjects (51-75%) at the final visit as compared to baseline (Fig. 1,2). In contrast, in the placebo group were rated as scale 0 improvement (0-25%).\u0000\u0000Conclusion: PRP injection for FPHL is a simple, cost-effective and feasible treatment option with good safety profile. However more randomized and multicentric trials with a large number of patients will be required to prove the validity of these results, to obtain these answers and to get more robust statistical results.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75451616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Dermatological manifestations are extremely polymorphic, increasingly reported on Caucasian skin. Few studies have been conducted on phototype VI which justifies our work whose objectives were to study the epidemiological, clinical, evolutionary aspects of dermatological manifestations on phototype VI. Methods: This was a descriptive retrospective study over a period of 1 year (March 3, 2020-March 3, 2021). Included were all patient records hospitalized for SARS-CoV-2 infection confirmed by Polymerase Chain Reaction (PCR), with acute dermatosis. Chronic dermatoses were not included. The data was collected and analyzed with the Epi info 2000 version 7.2.4.0 software. Results: Out of the 469 hospitalized patient records, 26 had dermatosis or 5.54%. The average age was 56.57 years (32-80 years). The sex ratio was 1.88. The following history was found: diabetes 38.46 (n=10), high blood pressure 26.92% (n=7), cancer 7.69% (n=2) and retroviral terrain 7.69% (n=2). The following dermatological manifestations were found: Pruritus: 30.76%, urticarial: 11.53%, smudges-papules: 3.84%, vesicles: 7.69%, vaso-occlusive lesions: 7 69%, other inflammatory lesions: 26.92%. The average length of hospitalization was 13.34 days with extremes of 7 to 22 days. The treatment used was azitromycin and hydroxychloroquine in 100%. Healing was noted in 96.15% with one death or 3.84%. Conclusion: Skin manifestations during COVID are polymorphic and could potentially reflect a full spectrum of viral interactions with the skin. Large-scale studies would help to elucidate the prognostic factors of these skin manifestations.
皮肤的表现是极其多样的，越来越多的报道在高加索皮肤。很少有关于光型VI的研究，这证明了我们的工作是正确的，我们的目标是研究光型VI皮肤病学表现的流行病学、临床和进化方面。方法:这是一项为期1年(2020年3月3日- 2021年3月3日)的描述性回顾性研究。纳入所有经聚合酶链反应(PCR)证实为SARS-CoV-2感染的住院患者，并伴有急性皮肤病。慢性皮肤病不包括在内。采用Epi info 2000 version 7.2.4.0软件进行数据收集和分析。结果:469例住院患者中有皮肤病26例，占5.54%。平均年龄56.57岁(32 ~ 80岁)。性别比为1.88。糖尿病38.46例(n=10)，高血压26.92% (n=7)，癌症7.69% (n=2)，逆转录病毒地形7.69% (n=2)。皮肤表现如下:瘙痒症占30.76%，荨麻疹占11.53%，斑点丘疹占3.84%，小泡占7.69%，血管闭塞病变占7.69%，其他炎性病变占26.92%。平均住院时间为13.34天，极值为7 ~ 22天。100%采用阿奇霉素和羟氯喹治疗。痊愈率为96.15%，死亡1例，占3.84%。结论:COVID期间的皮肤表现是多态的，可能反映了病毒与皮肤的全面相互作用。大规模的研究将有助于阐明这些皮肤表现的预后因素。
{"title":"Dermatological Manifestations during SARS-CoV-2 (COVID-19) on Phototype VI in Thiès/Senegal (West Africa)","authors":"P. Dioussé","doi":"10.46889/jdr.2022.3302","DOIUrl":"https://doi.org/10.46889/jdr.2022.3302","url":null,"abstract":"Introduction: Dermatological manifestations are extremely polymorphic, increasingly reported on Caucasian skin. Few studies have been conducted on phototype VI which justifies our work whose objectives were to study the epidemiological, clinical, evolutionary aspects of dermatological manifestations on phototype VI.\u0000\u0000Methods: This was a descriptive retrospective study over a period of 1 year (March 3, 2020-March 3, 2021). Included were all patient records hospitalized for SARS-CoV-2 infection confirmed by Polymerase Chain Reaction (PCR), with acute dermatosis. Chronic dermatoses were not included. The data was collected and analyzed with the Epi info 2000 version 7.2.4.0 software.\u0000\u0000Results: Out of the 469 hospitalized patient records, 26 had dermatosis or 5.54%. The average age was 56.57 years (32-80 years). The sex ratio was 1.88. The following history was found: diabetes 38.46 (n=10), high blood pressure 26.92% (n=7), cancer 7.69% (n=2) and retroviral terrain 7.69% (n=2). The following dermatological manifestations were found: Pruritus: 30.76%, urticarial: 11.53%, smudges-papules: 3.84%, vesicles: 7.69%, vaso-occlusive lesions: 7 69%, other inflammatory lesions: 26.92%. The average length of hospitalization was 13.34 days with extremes of 7 to 22 days. The treatment used was azitromycin and hydroxychloroquine in 100%. Healing was noted in 96.15% with one death or 3.84%.\u0000\u0000Conclusion: Skin manifestations during COVID are polymorphic and could potentially reflect a full spectrum of viral interactions with the skin. Large-scale studies would help to elucidate the prognostic factors of these skin manifestations.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79935350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Hand Eczema (HE) is the most common skin problem during SARS-CoV-2 pandemic which has impaired quality of life, impact work ability and cause hand dysfunction. The use of Topical Corticosteroid (TCS) alone can delay HE healing. Objective: To determine the efficacy of a semi-occlusive ointment containing panthenol, glycerol and bisabolol as an adjuvant therapy to TCS in mild-to-moderate HE. Methods: An open-label prospective study was conducted of 60 patients with mild-to-moderate HE. The tested product was applied to both hands, two or three times a day every 4 to 6 hours for 8 weeks. There was then a 4-week cessation period. Disease severity was assessed by physician/patient scoring systems, Corneometer, Tewameter and Visioscan that were collected at week 0, 2, 4, 8 and 12. Results: Fifty-six patients completed the study. The patients had a mean age of 42.8 years and were mostly female. The median duration of HE was 12.0 years. The physician and patient global assessment scores of clinical severity; erythema, dryness, itching and functional impairment, were significantly reduced starting at week 2 compared with baseline. After the 4-week cessation of the tested product, patient loosed the product efficacies. The proportion of patients who used TCS tended to decrease during the study period. Skin hydration was significantly improved at week 4. No unwanted effects found. Conclusion: A semi-occlusive healing ointment with panthenol, glycerol and bisabolol was effective and safe for treating mild-to-moderate HE. Our study identified an adjuvant ointment choice for HE treatment other than TCS.
{"title":"Clinical Efficacy and Skin Bioengineering Evaluations of a Semi-Occlusive Healing Ointment as an Adjuvant Therapy in Hand Eczema","authors":"S. Varothai","doi":"10.46889/jdr.2022.3301","DOIUrl":"https://doi.org/10.46889/jdr.2022.3301","url":null,"abstract":"Background: Hand Eczema (HE) is the most common skin problem during SARS-CoV-2 pandemic which has impaired quality of life, impact work ability and cause hand dysfunction. The use of Topical Corticosteroid (TCS) alone can delay HE healing.\u0000\u0000Objective: To determine the efficacy of a semi-occlusive ointment containing panthenol, glycerol and bisabolol as an adjuvant therapy to TCS in mild-to-moderate HE.\u0000\u0000Methods: An open-label prospective study was conducted of 60 patients with mild-to-moderate HE. The tested product was applied to both hands, two or three times a day every 4 to 6 hours for 8 weeks. There was then a 4-week cessation period. Disease severity was assessed by physician/patient scoring systems, Corneometer, Tewameter and Visioscan that were collected at week 0, 2, 4, 8 and 12.\u0000\u0000Results: Fifty-six patients completed the study. The patients had a mean age of 42.8 years and were mostly female. The median duration of HE was 12.0 years. The physician and patient global assessment scores of clinical severity; erythema, dryness, itching and functional impairment, were significantly reduced starting at week 2 compared with baseline. After the 4-week cessation of the tested product, patient loosed the product efficacies. The proportion of patients who used TCS tended to decrease during the study period. Skin hydration was significantly improved at week 4. No unwanted effects found.\u0000\u0000Conclusion: A semi-occlusive healing ointment with panthenol, glycerol and bisabolol was effective and safe for treating mild-to-moderate HE. Our study identified an adjuvant ointment choice for HE treatment other than TCS.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82271370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-27DOI: 10.46889/jdhor.2022.3212
Prema Sukumaran
Objective: This study was designed to use Optical Coherence Tomography (OCT) to quantify depth of occlusal fissures on premolar teeth and to quantitatively evaluate the penetration of pit and fissures sealants relative to fissure depth. The study aimed to evaluate the penetrability of Pit and Fissure Sealant (PFS) in covering the full-depth of different occlusal fissure depths using Swept-Source Optical Coherence Tomography (SS-OCT). Methods: Ninety-seven investigation sites on f occlusal fissures of fifteen premolar teeth with International Caries Detection and Assessment System (ICDAS) scores of 01 or 02 were categorized using SS-OCT into four groups (smooth, shallow, intermediate, and deep fissures). After PFS placement, cross-sectional images of these fissures were observed again with SS-OCT. Results: The result of this study shows that PFS can fully penetrate the smooth fissures (100%) followed by shallow fissures (94.2%) and intermediate fissures (47.6%). Incomplete full depth PFS penetration can be seen in all deep fissures (100%). Conclusion: The depth of the fissure will largely affect the penetrability of PFS into the fissure.
{"title":"Sealant Penetration into Occlusal Fissures: An In-Vitro Optical Coherence Tomography Study","authors":"Prema Sukumaran","doi":"10.46889/jdhor.2022.3212","DOIUrl":"https://doi.org/10.46889/jdhor.2022.3212","url":null,"abstract":"Objective: This study was designed to use Optical Coherence Tomography (OCT) to quantify depth of occlusal fissures on premolar teeth and to quantitatively evaluate the penetration of pit and fissures sealants relative to fissure depth. The study aimed to evaluate the penetrability of Pit and Fissure Sealant (PFS) in covering the full-depth of different occlusal fissure depths using Swept-Source Optical Coherence Tomography (SS-OCT).\u0000\u0000Methods: Ninety-seven investigation sites on f occlusal fissures of fifteen premolar teeth with International Caries Detection and Assessment System (ICDAS) scores of 01 or 02 were categorized using SS-OCT into four groups (smooth, shallow, intermediate, and deep fissures). After PFS placement, cross-sectional images of these fissures were observed again with SS-OCT.\u0000\u0000Results: The result of this study shows that PFS can fully penetrate the smooth fissures (100%) followed by shallow fissures (94.2%) and intermediate fissures (47.6%). Incomplete full depth PFS penetration can be seen in all deep fissures (100%).\u0000\u0000Conclusion: The depth of the fissure will largely affect the penetrability of PFS into the fissure.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75104886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Alopecia Areata (AA) is a common autoimmune disease leading to non-scarring hair loss. Previously, AA had been noted following various vaccinations including influenza virus, hepatitis B virus, herpes zoster virus, human papillomavirus, Japanese encephalitis, and Clostridium tetani. During this pandemic, AA following SARS-CoV-2 vaccine injection was rarely reported Objective: We report a case of diffuse AA and its trichoscopic findings following COVID-19 mRNA-1273 vaccination. Method: A trichoscopic examination of the scalp was performed. An English literature review through PubMed and an online search of the Vaccine Adverse Event Reporting System (VAERS) database were conducted. Finding: Only 20 patients of AA following SARS-CoV-2 vaccination were reported in the English literature. Black dots and broken hair were the most common features, followed by yellow dots and exclamation mark hairs. The VAERS database showed 77.8% were associated with the BNT162b2 vaccine and 20.9% with the COVID-19 mRNA-1273 vaccine, respectively. Conclusion: A rare case of AA and its trichoscopic findings following COVID-19 mRNA-1273 vaccine injection was reported. The COVID-19 vaccines may play a role in various immune-related dermatologic conditions.
{"title":"Diffuse Alopecia Areata and Its Trichoscopic Findings Following COVID-19 mRNA-1273 Vaccination: A Case Report","authors":"H. Chen","doi":"10.46889/jdr.2022.3212","DOIUrl":"https://doi.org/10.46889/jdr.2022.3212","url":null,"abstract":"Background: Alopecia Areata (AA) is a common autoimmune disease leading to non-scarring hair loss. Previously, AA had been noted following various vaccinations including influenza virus, hepatitis B virus, herpes zoster virus, human papillomavirus, Japanese encephalitis, and Clostridium tetani. During this pandemic, AA following SARS-CoV-2 vaccine injection was rarely reported\u0000\u0000Objective: We report a case of diffuse AA and its trichoscopic findings following COVID-19 mRNA-1273 vaccination.\u0000\u0000Method: A trichoscopic examination of the scalp was performed. An English literature review through PubMed and an online search of the Vaccine Adverse Event Reporting System (VAERS) database were conducted.\u0000\u0000Finding: Only 20 patients of AA following SARS-CoV-2 vaccination were reported in the English literature. Black dots and broken hair were the most common features, followed by yellow dots and exclamation mark hairs. The VAERS database showed 77.8% were associated with the BNT162b2 vaccine and 20.9% with the COVID-19 mRNA-1273 vaccine, respectively.\u0000\u0000Conclusion: A rare case of AA and its trichoscopic findings following COVID-19 mRNA-1273 vaccine injection was reported. The COVID-19 vaccines may play a role in various immune-related dermatologic conditions.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"280 5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86627134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Histoplasmosis caused by Histoplasma capsulatum var. duboisii is a deep mycosis that is rampant in Africa. Clinical manifestations are dominated by skin involvement. It is a condition that sometimes poses diagnostic and therapeutic problems. Observation: We report the case of an 81-year-old non-smoking, non-alcoholic patient who presented with polymorphic cutaneous lesions in the form of gums of variable size disseminated on the trunk and the limbs at the stage of rawness or softening, an ulcerative lesion crusty measuring 5 cm on its longest axis sitting at the level of the abdomen and an ulceration measuring 6 cm on its longest axis with purulent and hemorrhagic background with raised edges and indurated base at the level of the right subclavicular region. This picture had been evolving for 9 months in a context of impaired general condition and exertional dyspnoea at stage IV. Pulmonary examination revealed bilateral pleural effusion syndrome. Examination of the lymph nodes revealed no superficial adenopathy. African histoplasmosis was suggested. Retroviral serology and syphilitic serology were negative. The thoraco-abdomino-pelvic computed tomography showed a tumoral process at the apical level of the right lung at the level of the ventral segment of the upper lobe and multiple secondary localizations in the right mediastino-hilar lymph nodes under the skin and bone. The diagnosis of histoplasmosis was retained by the pathological examination of the skin biopsy, which was in favor of histoplasmosis and mycology confirmed histoplasmosis due to Histoplasma capsulatum var. dubosii. The evolution was marked by the death of the patient before the treatment. Conclusion: African histoplasmosis remains a rare condition although a few cases are reported in the literature. Its clinical polymorphism often confuses practitioners.
{"title":"Histoplasmosis Due to Histoplasma Capsulatum Var. Duboisii: Diagnostic Difficulties in Decentralized Areas","authors":"H. Dione","doi":"10.46889/jdr.2022.3211","DOIUrl":"https://doi.org/10.46889/jdr.2022.3211","url":null,"abstract":"Introduction: Histoplasmosis caused by Histoplasma capsulatum var. duboisii is a deep mycosis that is rampant in Africa. Clinical manifestations are dominated by skin involvement. It is a condition that sometimes poses diagnostic and therapeutic problems.\u0000\u0000Observation: We report the case of an 81-year-old non-smoking, non-alcoholic patient who presented with polymorphic cutaneous lesions in the form of gums of variable size disseminated on the trunk and the limbs at the stage of rawness or softening, an ulcerative lesion crusty measuring 5 cm on its longest axis sitting at the level of the abdomen and an ulceration measuring 6 cm on its longest axis with purulent and hemorrhagic background with raised edges and indurated base at the level of the right subclavicular region. This picture had been evolving for 9 months in a context of impaired general condition and exertional dyspnoea at stage IV. Pulmonary examination revealed bilateral pleural effusion syndrome. Examination of the lymph nodes revealed no superficial adenopathy. African histoplasmosis was suggested. Retroviral serology and syphilitic serology were negative. The thoraco-abdomino-pelvic computed tomography showed a tumoral process at the apical level of the right lung at the level of the ventral segment of the upper lobe and multiple secondary localizations in the right mediastino-hilar lymph nodes under the skin and bone. The diagnosis of histoplasmosis was retained by the pathological examination of the skin biopsy, which was in favor of histoplasmosis and mycology confirmed histoplasmosis due to Histoplasma capsulatum var. dubosii. The evolution was marked by the death of the patient before the treatment.\u0000\u0000Conclusion: African histoplasmosis remains a rare condition although a few cases are reported in the literature. Its clinical polymorphism often confuses practitioners.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86957941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction and aim: Getting an accurate diagnosis in dermatopathology requires a combination of clinical and pathological information. Our aim was to assess the importance of the correlation between clinical and histopathological diagnosis in various cutaneous diseases. Materials and Methods: One-hundred cases of variable skin diseases were studied clinically by dermatologist and histopathologically by general pathologists. Cliniopathological correlation was done by direct communication between the dermatologist and the pathologist. Results: Concordance between pathological and clinical diagnoses was seen in 84%, a new pathological diagnosis was issued in 3% and non-diagnostic report in 13 %. After clinicopathological correlation; out of 84%, we accept only 65% as final diagnosis. In addition, the correlation was helpful and provide a diagnosis in another 20% of cases. One new pathological diagnosis was accepted whereas in the remaining cases (14%) further workup were required. Conclusions: Accurate diagnosis of cutaneous disorders depends on clinical skills as well as careful histopathological assessment and best results can be obtained if the patient and biopsy sections are viewed together. Electron microscopy, immunofluorescence assay, immunohistochemistry techniques and molecular pathology are important adjuncts for definite diagnosis of many skin diseases.
{"title":"Clinicopathological Correlation in Dermatopathology","authors":"Safa Suleman El Faituri","doi":"10.46889/jdr.2022.3210","DOIUrl":"https://doi.org/10.46889/jdr.2022.3210","url":null,"abstract":"Introduction and aim: Getting an accurate diagnosis in dermatopathology requires a combination of clinical and pathological information. Our aim was to assess the importance of the correlation between clinical and histopathological diagnosis in various cutaneous diseases.\u0000\u0000Materials and Methods: One-hundred cases of variable skin diseases were studied clinically by dermatologist and histopathologically by general pathologists. Cliniopathological correlation was done by direct communication between the dermatologist and the pathologist.\u0000\u0000Results: Concordance between pathological and clinical diagnoses was seen in 84%, a new pathological diagnosis was issued in 3% and non-diagnostic report in 13 %. After clinicopathological correlation; out of 84%, we accept only 65% as final diagnosis. In addition, the correlation was helpful and provide a diagnosis in another 20% of cases. One new pathological diagnosis was accepted whereas in the remaining cases (14%) further workup were required.\u0000\u0000Conclusions: Accurate diagnosis of cutaneous disorders depends on clinical skills as well as careful histopathological assessment and best results can be obtained if the patient and biopsy sections are viewed together. Electron microscopy, immunofluorescence assay, immunohistochemistry techniques and molecular pathology are important adjuncts for definite diagnosis of many skin diseases.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85982024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：